Allspring Global Investments Holdings LLC Cuts Stock Holdings in Guardian Pharmacy Services, Inc. $GRDN

Allspring Global Investments Holdings LLC reduced its position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 29.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,599 shares of the company’s stock after selling 61,356 shares during the period. Allspring Global Investments Holdings LLC owned 0.23% of Guardian Pharmacy Services worth $4,240,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in shares of Guardian Pharmacy Services by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock worth $30,000,000 after purchasing an additional 36,072 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Guardian Pharmacy Services by 8.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock worth $27,705,000 after purchasing an additional 80,033 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Guardian Pharmacy Services by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock worth $27,675,000 after purchasing an additional 88,296 shares during the last quarter. Boston Partners boosted its holdings in shares of Guardian Pharmacy Services by 418.7% during the 3rd quarter. Boston Partners now owns 1,046,877 shares of the company’s stock worth $26,922,000 after purchasing an additional 845,048 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its holdings in shares of Guardian Pharmacy Services by 5.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 860,173 shares of the company’s stock worth $22,562,000 after purchasing an additional 45,950 shares during the last quarter.

Insiders Place Their Bets

In other Guardian Pharmacy Services news, Director Thomas J. Salentine, Jr. sold 3,570,677 shares of the stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $105,977,693.36. Following the completion of the transaction, the director owned 4,469,316 shares of the company’s stock, valued at $132,649,298.88. This trade represents a 44.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Fred Burke sold 671,432 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $19,928,101.76. Following the transaction, the insider directly owned 840,413 shares of the company’s stock, valued at approximately $24,943,457.84. This trade represents a 44.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 9,726,405 shares of company stock worth $288,679,700. Corporate insiders own 63.71% of the company’s stock.

Guardian Pharmacy Services Stock Performance

GRDN stock opened at $39.12 on Wednesday. The firm has a market cap of $2.48 billion, a PE ratio of 50.81 and a beta of 0.47. The firm’s 50 day moving average price is $34.08 and its 200-day moving average price is $30.46. Guardian Pharmacy Services, Inc. has a one year low of $19.17 and a one year high of $39.53.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.27 by $0.10. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The business had revenue of $397.62 million for the quarter, compared to analyst estimates of $390.04 million. The company’s revenue for the quarter was up 17.4% on a year-over-year basis. Equities research analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on GRDN. Truist Financial upped their target price on Guardian Pharmacy Services from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Oppenheimer upped their target price on Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Stephens upped their target price on Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, January 14th. Zacks Research upgraded Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, UBS Group restated a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Guardian Pharmacy Services presently has a consensus rating of “Buy” and a consensus price target of $39.20.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.